An Open-Label, Multicenter, Phase II Clinical Trial Evaluating the Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Trial Profile

An Open-Label, Multicenter, Phase II Clinical Trial Evaluating the Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2017 New trial record
    • 06 Sep 2017 According to a Verastem media release, the company intends to initiate this trial by year end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top